VibroSense Dynamics AB (publ) announces today that a distribution agreement has been signed with Sparqmed, a newly started medical device distributor based in Warsaw, Poland. The agreement grants Sparqmed the right to market and sell VibroSense products in the Polish market.
Poland is an important market with significant potential in diabetes care and occupational health. The country has over 3 million diagnosed diabetics and a growing awareness of the need for early neurological diagnostics. The agreement with Sparqmed is a step in VibroSense continued European expansion.
Poland ranks among the European countries with the highest rates of lower-extremity amputations in diabetic patients, according to data from the Polish National Health Fund. A national pilot programme for diabetic foot treatment has been extended and is currently operating across six hospitals in the country, with the aim of reversing the alarming amputation statistics. Early diagnosis of peripheral neuropathy is central to this effort, and precisely the clinical need that VibroSense Meter® II is designed to address.
"We look forward to the collaboration with Sparqmed and are confident that VibroSense Meter® II can make a real difference for patients in Poland", says Toni Speidel, CEO of VibroSense Dynamics AB.
For more information, please contact:
Toni Speidel, CEO
VibroSense Dynamics AB (publ)
Phone: +46 40 88 026
Email: info@vibrosense.com
Website: www.vibrosense.com
"The new Gold Standard for reliable
detection of nerve damage"
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.
Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.